MAPK3 and asthma: IL-17A and IL4 have a potential synergistic effect with TGF-β1 in inducing bronchial EMT, p-Smad3 expression and ERK1/2 signaling pathway activation, and inhibiting E-cadherin mRNA expression in the setting of severe asthma [84].